P1165Development and Validation of a screening tool to address dietary habits in persons with IBD in Germany

Background Dietary habits play a pivotal role in the development and course of disease in patients with inflammatory bowel disease (IBD). However, standardised nutritional assessments are often time consuming and require the involvement of professional dietitians, resulting in a substantial gap in the ability to screen for crucial dietary factors. Therefore, these aspects tend to be overlooked in both clinical practice and research. In order to address this issue, we developed a short screening instrument with 31 questions (22 semiquantitative and 9 qualitative items) assessing dietary patterns and nutritional aspects of dietary habits in patients with IBD (“Ernährungsscreener für Chronisch-entzündliche Darmerkrankungen – ESCED”). Acceptability and comprehensibility of the screening tool were evaluated by outpatients with IBD in a previous phase, and validity and reliability of the revised version of the screener were then assessed in a multicentric setting. Methods Participants with IBD on stable treatment regime from three German tertiary IBD centres in Mannheim, Hannover and Munich were asked to complete the ESCED at enrolment and again after four weeks. During this period, the study teams contacted participants at least five times on different days of the week to conduct 24-hour dietary recalls via telephone interviews. This preliminary evaluation analysed stability of the screening tool by comparing baseline and follow-up data, and construct validity by comparing follow-up data with recall results. Results We analysed data of n = 214 patients (n = 81 female, n = 131 with Crohn’s Disease), with a median disease duration of 14.1 years. Test-retest comparison of the questionnaire showed good stability with >87% of patients answering all ordinal items in the follow-up with a maximum deviation of one point per item. For construct validity assessment (comparison between follow-up questionnaire data and questionnaires completed by the study team based on dietary recalls) we found concordance with a maximum deviation of 1 point for all ordinal items in > 82% of patients. Spearman rank correlation analyses yielded statistically significant positive correlations for test-retest reliability (ρ = .47 to ρ = .83) and construct validity (ρ = .19 to ρ = .82) for all ordinal items (p < .001 for all comparisons). Conclusion We developed a novel brief screening tool with 31 items for dietary and nutritional aspects in IBD that demonstrated test–retest reliability and construct validity in the interim analysis, supporting its future use in both clinical practice and research settings in German-speaking patients. Conflict of interest: Dr. Wilke, Eva Lina: Abbvie - coverage of training fees (Skills Lab 2025) Johnsson & Johnsson - coverage of training fees and travel expences (CEDexperts 23/24), congress registration fees (ECCO 2025) Gilead - coverage of training fees (Campus Infektiologie 2023), AbbVie and Ferring (participation in the DACED conferences 2023, 2024) Kala, Yilmaz Rohat: No conflict of interest. Atanasova, Konstantina: Fees: Abbvie, Alfasigma, Amgen, Janssen-Cilag, Lilly, Takeda, Tillot Knödler, Laura-Louise: Fees for preparing presentations: presentation at CED compact 2024 and CED compact 2025: CED Service GmbH Reimbursement of participation fees for education courses: Janssen Cilag (participation in the CEDxperts program 2021-2022), AbbVie (participation in the CED Skills Lab 2025), AbbVie and Ferring (participation in the DACED conferences) Grants: Clinician Scientist Program ICON: University of Heidelberg Medical Faculty Mannheim Fuhrberg, Stefanie Claire: No conflicts Pueschel, Lea: No conflicts Kuhn, Leonie: No conflicts Conrad, Josephine: No conflicts Florea, Marina: Takeda Pharma Vertrieb GmbH, Abbvie, Dr. Falk Pharma, Galapagos Biopharma Germany GmbH/Alfasigma, Janssen Pharmaceutica Schemann, Linda: no conflict of interest Ebert, Matthias Philip: No conflict of interest. Middelhoff, Moritz: None. Wiestler, Miriam: Financial compensation for lectures, advisory boards, other medical-scientific services by: AbbVie, Alfasigma, CED Service, Dr. Falk Pharma, FomF Forum für medizinische Fortbildung, FORUM Institut für Management GmbH, Johnson & Johnson, Lilly Deutschland GmbH, Pfizer, Takeda Pharma. Reindl, Wolfgang: Speaker fees from Janssen, Abbvie, Takeda, MSD,Falk Advisory fees Janssen, Abbvie, Takeda Thomann, Anne: Personal Fees: Speakers honoraria and/or advisory boards: Alfasigma, Abbvie, Falk Foundation, Ferring, Galapagos, Hexal, Janssen/J&J, Takeda Non-financial Support: Travel support: Allergosan, Janssen/J&J, Takeda, Abbvie